COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord |
| |
| Authors: | Yiangos Yiangou Paul Facer Pascal Durrenberger Iain P Chessell Alan Naylor Chas Bountra Richard R Banati Praveen Anand |
| |
| Institution: | (1) Peripheral Neuropathy Unit, Imperial College, Hammersmith Hospital, London, UK;(2) GastrointestinaI Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, Harlow, UK;(3) School of Medical Radiation Sciences and Ramaciotti Centre for Brain Imaging, Brain-Mind Research Institute, University of Sydney, New South Wales, Australia |
| |
| Abstract: | Background While multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are primarily inflammatory and degenerative disorders
respectively, there is increasing evidence for shared cellular mechanisms that may affect disease progression, particularly
glial responses. Cyclooxygenase 2 (COX-2) inhibition prolongs survival and cannabinoids ameliorate progression of clinical
disease in animal models of ALS and MS respectively, but the mechanism is uncertain. Therefore, three key molecules known
to be expressed in activated microglial cells/macrophages, COX-2, CB2 and P2X7, which plays a role in inflammatory cascades,
were studied in MS and ALS post-mortem human spinal cord. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
